Literature DB >> 25998390

Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation.

Masakazu Kamata1, Patrick Y Kim2, Hwee L Ng3, Gene-Errol E Ringpis2, Emiko Kranz2, Joshua Chan2, Sean O'Connor2, Otto O Yang4, Irvin S Y Chen5.   

Abstract

Chimeric antigen receptors (CARs) are artificially engineered receptors that confer a desired specificity to immune effector T cells. As an HIV-1-specific CAR, CD4ζ CAR has been extensively tested in vitro as well as in clinical trials. T cells modified with this CAR mediated highly potent anti-HIV-1 activities in vitro and were well-tolerated in vivo, but exerted limited effects on viral load and reservoir size due to poor survival and/or functionality of the transduced cells in patients. We hypothesize that ectopic expression of CD4ζ on CD8(+) T cells renders them susceptible to HIV-1 infection, resulting in poor survival of those cells. To test this possibility, highly purified CD8(+) T cells were genetically modified with a CD4ζ-encoding lentiviral vector and infected with HIV-1. CD8(+) T cells were vulnerable to HIV-1 infection upon expression of CD4ζ as evidenced by elevated levels of p24(Gag) in cells and culture supernatants. Concurrently, the number of CD4ζ-modified CD8(+) T cells was reduced relative to control cells upon HIV-1 infection. To protect these cells from HIV-1 infection, we co-expressed two anti-HIV-1 shRNAs previously developed by our group together with CD4ζ. This combination vector was able to suppress HIV-1 infection without impairing HIV-1-dependent effector activities of CD4ζ. In addition, the number of CD4ζ-modified CD8(+) T cells maintained similar levels to that of the control even under HIV-1 infection. These results suggest that protecting CD4ζ-modified CD8(+) T cells from HIV-1 infection is required for prolonged HIV-1-specific immune surveillance.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD4ζ; Chimeric antigen receptor (CAR); HIV-1; Immunotherapy; shRNA

Mesh:

Substances:

Year:  2015        PMID: 25998390      PMCID: PMC4686265          DOI: 10.1016/j.bbrc.2015.05.026

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  38 in total

Review 1.  Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells.

Authors:  N Bitton; G Gorochov; P Debre; Z Eshhar
Journal:  Front Biosci       Date:  1999-04-01

Review 2.  Biological aspects of HIV infection.

Authors:  B Macchi; M A Petruzzelli; V De Laurenzi
Journal:  Clin Ter       Date:  1992-02

3.  Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010.

Authors:  Hildegund C J Ertl; John Zaia; Steven A Rosenberg; Carl H June; Gianpietro Dotti; Jeffrey Kahn; Laurence J N Cooper; Jacqueline Corrigan-Curay; Scott E Strome
Journal:  Cancer Res       Date:  2011-05-01       Impact factor: 12.701

4.  Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

Authors:  R E Walker; C M Bechtel; V Natarajan; M Baseler; K M Hege; J A Metcalf; R Stevens; A Hazen; R M Blaese; C C Chen; S F Leitman; J Palensky; J Wittes; R T Davey; J Falloon; M A Polis; J A Kovacs; D F Broad; B L Levine; M R Roberts; H Masur; H C Lane
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

5.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Authors:  Steven G Deeks; Bridget Wagner; Peter A Anton; Ronald T Mitsuyasu; David T Scadden; Christine Huang; Catherine Macken; Douglas D Richman; Cindy Christopherson; Carl H June; Richard Lazar; David F Broad; Sayeh Jalali; Kristen M Hege
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

6.  Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6.

Authors:  P Lusso; A De Maria; M Malnati; F Lori; S E DeRocco; M Baseler; R C Gallo
Journal:  Nature       Date:  1991-02-07       Impact factor: 49.962

7.  Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes.

Authors:  A C Tran; D Zhang; R Byrn; M R Roberts
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

8.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

9.  96 shRNAs designed for maximal coverage of HIV-1 variants.

Authors:  Glen John McIntyre; Jennifer Lynne Groneman; Yi-Hsin Yu; Angel Jaramillo; Sylvie Shen; Tanya Lynn Applegate
Journal:  Retrovirology       Date:  2009-06-04       Impact factor: 4.602

Review 10.  Cytopathic mechanisms of HIV-1.

Authors:  Joshua M Costin
Journal:  Virol J       Date:  2007-10-18       Impact factor: 4.099

View more
  9 in total

1.  Engineering HIV-Specific Immunity with Chimeric Antigen Receptors.

Authors:  Scott G Kitchen; Jerome A Zack
Journal:  AIDS Patient Care STDS       Date:  2016-12       Impact factor: 5.078

Review 2.  Chimeric antigen receptor T-cell approaches to HIV cure.

Authors:  Anne-Sophie Kuhlmann; Christopher W Peterson; Hans-Peter Kiem
Journal:  Curr Opin HIV AIDS       Date:  2018-09       Impact factor: 4.283

Review 3.  Chimeric antigen receptor engineered stem cells: a novel HIV therapy.

Authors:  Anjie Zhen; Mayra A Carrillo; Scott G Kitchen
Journal:  Immunotherapy       Date:  2017-03       Impact factor: 4.196

Review 4.  Cell and gene therapy strategies to eradicate HIV reservoirs.

Authors:  Chelsea Spragg; Harshana De Silva Feelixge; Keith R Jerome
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

Review 5.  CAR T cells for infection, autoimmunity and allotransplantation.

Authors:  Colby R Maldini; Gavin I Ellis; James L Riley
Journal:  Nat Rev Immunol       Date:  2018-10       Impact factor: 53.106

Review 6.  Engineering CAR T Cells to Target the HIV Reservoir.

Authors:  Wenli Mu; Mayra A Carrillo; Scott G Kitchen
Journal:  Front Cell Infect Microbiol       Date:  2020-08-13       Impact factor: 5.293

7.  Efficient derivation of chimeric-antigen receptor-modified TSCM cells.

Authors:  Emiko Kranz; Charles J Kuhlmann; Joshua Chan; Patrick Y Kim; Irvin S Y Chen; Masakazu Kamata
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

8.  Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir.

Authors:  Madhu C Choudhary; Joshua C Cyktor; Sharon A Riddler
Journal:  J Virus Erad       Date:  2022-06-18

Review 9.  Advances in Developing CAR T-Cell Therapy for HIV Cure.

Authors:  Jinxin Qi; Chengchao Ding; Xian Jiang; Yong Gao
Journal:  Front Immunol       Date:  2020-03-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.